Concord Biotech Quarterly Results for Trading Insights
In Mar 2026, Concord Biotech (CONCORDBIO) reported revenue ₹341 Cr and net profit ₹89 Cr — revenue -22.3% YoY. Check CONCORDBIO market cap trends to track the company's total market size over time.
CONCORDBIO Quarterly Results — Revenue, Profit & EPS Highlights
Concord Biotech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Concord Biotech share price chart.
- Revenue of ₹341 Cr in Mar 2026 (+25.4% vs Jun 2026, -22.3% vs Mar 2025)
- Net Profit of ₹89 Cr in Mar 2026 (+53.4% vs Jun 2026, -36.4% vs Mar 2025)
- EBITDA of ₹134 Cr in Mar 2026 (+38.1% vs Jun 2026)
- Operating Margin of 36.0% in Mar 2026 (+4.0pp vs Jun 2026)
- Earnings Per Share of ₹8.46 in Mar 2026 (+53.3% vs Jun 2026)
Concord Biotech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CONCORDBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 341 | 272 | 263 | 439 | 219 | 25.4% | -22.3% |
| Net Profit (₹ Cr) | 89 | 58 | 63 | 140 | 44 | - | - |
| EBITDA (₹ Cr) | 134 | 97 | 104 | 198 | 77 | - | - |
| EPS (₹) | 8.46 | 5.52 | 6.03 | 13.42 | 4.21 | - | - |
| Operating Margin (%) | 36.0% | 32.0% | 36.0% | 44.0% | 30.0% | - | - |
CONCORDBIO Share Price Trend — 1-Year Movement Across Quarterly Results
Concord Biotech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse CONCORDBIO shareholder distribution to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CONCORDBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Concord Biotech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹456,449.48 Cr | 1922.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 170.1 |
|
Divis Laboratories
Mar 2026 |
₹225,542.11 Cr | 8744.5 | 2,986 | 751 | -5.0% | - | 25.2% | 308.9 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4932.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 428.5 |
|
Cipla
Mar 2026 |
₹115,699.61 Cr | 1422.0 | 6,612 | 543 | -9.3% | - | 8.2% | 207.0 |
|
Zydus Life Science
Mar 2026 |
₹111,068.11 Cr | 1124.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.9 |
All amounts in ₹ Crores